 Feel better  Live longer  To improve quality of life (symptoms)  To reduce mortality  To reduce morbidity  To reduce progression of disease and.

Slides:



Advertisements
Similar presentations
MEDPHARM DRUGS FOR ISCHEMIC HEART DISEASE FEBRUARY 10,2110.
Advertisements

ANGINA PECTORIS. Angina pectoris (chest pain) is the result of myocardial ischemia caused by an imbalance between myocardial blood supply and oxygen demand.
Drugs to treat angina. I. Introduction Branching off the aorta are the coronary arteries.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 51 Drugs for Angina Pectoris.
Chronic stable angina Dr Taban Internist & cardiologist.
Ischemic Heart Disease.  Coronary artery disease CAD is a general manifestation that dose not discriminate bet the various phases that the individual.
Management of Stable Angina Pectoris David Putnam, MD Albany Medical College.
CORONARY CIRCULATION DR. Eman El Eter.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Ischemic heart disease
Ischemic Heart Diseases IHD
Angina Pectoris “Chest pain” or angina pectoris is a symptom of ischemic heart disease caused by an imbalance between oxygen requirement of the heart and.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Beta Blockade and the Heart John Hakim, M.D Cardiology Fellow West Virginia University Division of Cardiology.
Drugs for CCF Heart failure is the progressive inability of the heart to supply adequate blood flow to vital organs. It is classically accompanied by significant.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Chapter 18 Agents that Dilate Blood Vessels. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Coronary.
Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
C.H.T Dr.Salarifar 1 Tehran Heart Center Tehran University of Medical Sciences PCI VS CABG M. SALARIFAR, MD.
Cardio pharmacology Angina. angina Causes Atheroma Others: Aortic stenosis, aberrant coronary circulation, severe anaemia, arteritis Prevention Decrease.
CORONARY CIRCULATION DR. Eman El Eter. Coronary Arteries The major vessels of the coronary circulation are: 1- left main coronary that divides into left.
Dr Jayachandran Thejus.  Coronary artery disease-  Block in coronary artery due to plaque or thrombus  Leads to myocardial ischemia manifested as chest.
1 ANGINA ANGINA MYOCARDIAL OXY. DEMAND >. OXY. SUPPLY. OXY. SUPPLY < SYMPTOMS – chest pain mostly relieved by taking rest, dyspnea, sweating, nausea..
Ischemic Heart Diseases
Management of Stable Angina Pectoris Bushra Abdul Hadi.
Management of Stable Angina SIGN 96
Drugs in the Therapy of Angina Dr. Thomas Abraham PHAR417: Fall 2004.
Risk stratification and secondary prevention following acute myocardial infarction In-Ho Chae Department of Internal Medicine Seoul National University.
 Hypertension : BPDIASTOLIC SYSTOLIC Normal< 130< 85 Mild hypertension Moderate hypertension Severe Hypertension 180.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36.
CARDIOVASCULAR CARE of the OUTPATIENT Diane M. Enzweiler, MSN, ANP-BC St. Elizabeth Physicians: Heart and Vascular.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
2. Ischaemic Heart Disease.
Agents that Dilate Coronary Blood Vessels.  Coronary artery disease (CAD) results from atherosclerosis  Clinical symptoms caused by  narrowing of the.
Antianginal Drugs Learning outcomes Recognize variables contributing to a balanced myocardial supply versus demand Expand on the drugs used to alleviate.
Drug Treatment of Ischemic Heart Disease Fixed "Stable" Angina Variant Angina Unstable Angina Myocardial Infarction.
for more lecture notes Antianginal Agents Dr.Shadi-Sarahroodi Pharm.D & PhD Qom University of Medical sciences Iran PUBLISHED.
They bind to the channel from the inner side of the membrane. They bind to channels in depolarized membranes. Binding  ↓ frequency of opening of the channels.
ANGINA PECTORIS Tb Tuberculosis Carl Matol, RN. ANGINA-to choke CLASSIC/STABLE ANGINA Due to insufficiency of O2 supply against myocardial demand Accumulated.
Antianginal drugs Angina pectoris is the severe chest pain that occurs when coronary blood flow is inadequate to supply the oxygen required by the heart.
Angina pectoris Sudden,severe,pressing chest pain starting substernal &radiate to left arm. Due to imbalance between myocardium oxygen requirement and.
Diabetes Mellitus 101 for Medical Professionals
Ischemic heart diseases Ischemia : it is inadequate supply of O2 to an organ or tissue (result from inadequate blood flow) insufficient to meet the organ’s.
Angina pectoris Sudden, severe, pressing chest pain and radiating to the neck, jaw, back, and arms. The episodes are transient, stay between 15 sec to.
 Heart disease remains the leading cause of morbidity and mortality in industrialized nations.  40% of all deaths in the U.S.A (nearly twice the number.
MYOCARDIAL INFARCTION. CASE 1 Mr. A: 38 years old He smokes 1 pack of cigarettes per day He has no other past medical history 8 hours ago, he gets sharp.
Antianginal drugs Antidysrrhytmic drugs
Angina pectoris Sudden,severe,pressing chest pain starting substernal &radiate to left arm & neck. Due to imbalance between myocardium oxygen requirement.
Michelle Gardner RN NUR-224. OBJECTIVES  Define normal blood pressure and categories of abnormal pressure  Identify risk factors for hypertension 
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.1 Drugs for Angina Pectoris.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Drugs for Angina Pectoris
ANGINA PECTORIS Classic angina is characterized by substernal squeezing chest pain, occurring with stress and relieved with rest or nitroglycerin. May.
Lesson 11.2 congenital heart disease (CHF) Atherosclerosis
Ranolazine The mechanism of action of ranolazine has not been determined, but it may be related to reduction in calcium overload in ischemic myocytes.
Antianginal Drugs Learning outcomes
Anti-Anginal Drugs.
Antianginal Drugs Learning outcomes
Formative Test.
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.
Anti-Anginal Drugs.
Antianginal Drugs.
Antianginal Drugs Ass. Prof. Naza M. Ali Lec 3-4 G2 21 April 2019
Drugs Used to Treat Angina Pectoris
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
Presentation transcript:

 Feel better  Live longer

 To improve quality of life (symptoms)  To reduce mortality  To reduce morbidity  To reduce progression of disease and induce regression.

 Left ventricular function  Number of coronary arteries with significant stenosis  Extent of jeoporized myocardium

Risk stratification  Noninvasive testing  Cardiac catheterization

 Physical exam  CXR  Echocardiogram

 History  Baseline Electrocardiogram  Exercise Testing

 Class I  Class II  Class III  Class IV  Angina only with extreme exertion  Angina with walking 1 to 2 blocks  Angina with walking 1 block  Angina with minimal activity

 Hypertension  Smoking  Dyslipidemia  Diabetes Mellitus  Obesity  Stress  Homocysteine

Treatment of Chronic Stable Angina Medical Revascularization PCIACBG

 Medical Treatment

 ANTIPLATELETS  BETA BLOCKERS  NITRATES  CALCIUM ANTAGONIST  ACEI  STATINS  NEW THERAPIES

 Effect on myocardium  Effect on cardiac conduction system  Effect on coronary/systemic arteries  Effect on venous capitance system  Circadian rhytm

 1. Aspirin in the absence of contraindications A  2. Beta-blockers as initial therapy in the absence of contraindications in patients with prior myocardial infarction or without prior myocardial infarction A,B  3. ACE inhibitor in all patients with CAD who also have diabetes and/or LV systolic dysfunction A  4. LDL-lowering therapy in patients with documented or suspected CAD and LDL cholesterol >130 mg/dl, with a target LDL of <70 mg/dl A  5. Sublingual nitroglycerin or nitroglycerin spray for the immediate relief of angina B  6. Calcium antagonists † or long-acting nitrates as initial therapy for reduction of symptoms when beta blockers are contraindicated B†  7. Calcium antagonists † or long-acting nitrates in combination with beta blockers when initial treatment with beta blockers is not successful B †  8. Calcium antagonists † and long-acting nitrates as a substitute for beta blockers if initial treatment with beta blockers leads to unacceptable side effects†

 1. Clopidogrel when aspirin is absolutely contraindicated  2. Long-acting non-dihydropyridine calcium antagonists † instead of beta blockers as initial therapy B†  3. In patients with documented or suspected CAD and LDL cholesterol 100–129 mg/dl, several therapeutic options are available: B a. Lifestyle and/or drug therapies to lower LDL to <70 mg/dl b. Weight reduction and increased physical activity in persons with the metabolic syndrome c. Institution of treatment of other lipid or non-lipid risk factors; consider use of nicotinic acid or fibric acid for elevated triglycerides or low HDL cholesterol  4. ACE inhibitor in patients with CAD or other vascular disease

 Decrease myocardial oxygen consumption  Blunt exercise response  Beta-one drugs have theoretical advantage  Try to avoid drugs with intrinsic sympathomimetic activity  First line therapy in all patients with angina if possible

 Bronchospasm  Diminished exercise capacity  Negative inotropy  Sexual dysfunction  Bradyarrhythmia  Masking of hypoglycemia  Increased claudication  Hair loss

 Propranolol  Atenolol  Metoprolol  Carvediloll

 Arterial dilation/after-load reduction  Coronary arterial vasodilation  Prevention of coronary vasoconstriction  Enhancement of coronary collateral flow  Improved subendocardial perfusion  Slowing of heart rate with diltiazem, verapamil

 Palpitations  Headache  Ankle edema  Gingival hyperplasia

 Verapamil  Diltiazem  Nifedipine  Nicardipine  Amlodipine  Felodipine  Nisoldipine  Bepridil

 Nitric oxide has been identified as endothelium-derived relaxing factor  Organic nitrates are therapeutic precursors of endothelium-derived relaxing factor

 Venous vasodilation/pre-load reduction  Arterial dilation/after-load reduction  Coronary arterial vasodilation  Prevention of coronary vasoconstriction  Enhancement of coronary collateral flow  Antiplatelet and antithrombotic effects

 Smaller doses  Less frequent dosing  Avoidance of long-acting formulations unless a prolonged nitrate-free interval is provided  Build-in a nitrate-free interval o 8-12 hours

 Headache  Flushing  Palpitations  Tolerance

 Isorbide dinitrate  Isorbide mononitrate  Long-acting transdermal patches  Nitroglycerin sl

 1. Treatment of hypertension according to Joint National Conference VI guidelines A  2. Smoking cessation therapy B  3. Management of diabetes C  4. Comprehensive cardiac rehabilitation program (including exercise) B  5. LDL-lowering therapy in patients with documented or suspected CAD and LDL cholesterol ≥100 mg/dl, with a target LDL of <70 mg/dl A  6. Weight reduction in obese patients in the presence of hypertension, hyperlipidemia, or diabetes mellitus C

 Smoking Complete cessation  Blood pressure <140/90 or 130/85 mm Hg if heart failure or renal insufficiency; <130/85 mm Hg if diabetes  Lipid management Primary goal: LDL <70 mg/dl Secondary goal: If triglycerides ≥200 mg/dl, then non-HDL should be <130 mg/dl  Physical activity Minimum goal: 30 min 3 or 4 d/w Optimal goal: daily  Weight management BMI 18.5–24.9 kg/m2  Diabetes management HbA1c <7%

 CABG

 1. CABG for patients with significant left main coronary disease A  2. CABG for patients with triple-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction <0.50)A  3. CABG for patients with double-vessel disease with significant proximal LAD CAD and either abnormal LV function (ejection fraction less than 50%) or demonstrable ischemia on noninvasive testing A  4. Percutaneous coronary intervention for patients with double-or triple-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes B

 5. PCI or CABG for patients with single- or double-vessel CAD without significant proximal LAD CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing B  6. CABG for patients with single- or double-vessel CAD without significant proximal LAD CAD who have survived sudden cardiac death or sustained ventricular tachycardia C  7. In patients with prior PCI, CABG or PCI for recurrent stenosis associated with a large area of viable myocardium or high-risk criteria on noninvasive testing C  8. PCI or CABG for patients who have not been successfully treated by medical therapy and can undergo revascularization with acceptable risk B

 65% remain symptom-free at ten years  85% remain free of fatal/nonfatal MI at ten years  Mortality of 2-3% yearly over ten years  2.5% incidence of perioperative MI

 Three major randomized trials A. VACS B. ECSS C. CASS  Improved mortality in CABG group A. L-main CAD B. 3-vessel CAD, esp. with decreased EF C. LAD disease, severe angina, decreased EF

 PTCA

 80% or greater success rate  1% mortality  3-5% emergency CABG ( prior to stenting )  4% acute MI

 Initiate pharmacologic treatment A. Nearly half of patients will become asymptomatic  PTCA preferred alternative if medical therapy does not relieve angina or causes adverse effects

 Initial medical management in patients with mild ischemic symptoms and normal LV function  Revascularization in patients who fail medical therapy  Selection of PTCA vs. CABG depends on coronary anatomy, LV function, need for complete revascularization, and patient preference

 CABG in patients with left-main disease or 3-vessel CAD and decreased LVEF  PTCA or medical management an alternative in patients with 3-vessel CAD, mild symptoms, and preserved LVEF

NEW THERAPIES

 RANOLAZINE (Ranexa™; CV Therapeutics, Inc.), a drug that has been in development for 20 years. It is a Sodium Channel Blocker.  NICORANDIL, a potassium channel activator, and also has a Nitrogen Donating Moeity.  IVABRADINE, inhibits the I f channel in the sinus node and thereby causes bradycardia without any negative inotropic effects.

Ranolazine Consequences of ischemia Electrical instability Myocardial dysfunction ( ↓ systolic function/ ↑ diastolic stiffness) Conventional anti-ischemic medications ß blockers Nitrates Ca ++ blockers Compression of nutritive blood vessels Ischemia (Ca 2+ overload) ↑ O 2 demand Heart rate Blood pressure Preload Contractility ↓ O 2 supply Development of ischemia (Stone, 2004)

Diseases (eg, ischemia, heart failure) Pathological milieu (reactive O 2 species, ischemic metabolites) Toxins and drugs (eg, ATX-II, etc.) Na + channel (Gating mechanism malfunction) Increase ATP consumption Decrease ATP formation Oxygen supply and demand Abnormal contraction and relaxation ↑ diastolic tension ( ↑ LV wall stiffness) Mechanical dysfunction Early after potentials Beat-to-beat Δ APD Arrhythmias (VT) Electrical instability

Ischemia ↑ Late I Na Na + overload Diastolic relaxation failure (increased diastolic tension) Extravascular compression Ca 2+ overload Ranolazine inhibits the late inward Na current

 Surgical  surgeons use the laser to make between 20 and 40 tiny (one-millimeter-wide)

 Percutaneous

EECP

 Angina class III/IV Refractory to medical therapy Reversible ischemia of the free wall not amenable for revascularization  Excluded if LVEF<20% or had current major illness